The Sjögren-Larsson syndrome (SLS) is a rare autosomal recessive disorder caused by pathogenic variants in the ALDH3A2 gene, which codes for fatty aldehyde dehydrogenase (FALDH). FALDH prevents the accumulation of toxic fatty aldehydes by converting them into fatty acids. Pathogenic ALDH3A2 variants cause symptoms such as ichthyosis, spasticity, intellectual disability, and a wide range of less common clinical features.
INTRODUCTION
Sjögren-Larsson syndrome (SLS; MIM# 270200) is an autosomal recessive disorder caused by pathogenic loss-of-function variants (denoted "SLS variants") in the ALDH3A2 gene, which codes for the enzyme fatty aldehyde dehydrogenase (FALDH) Rizzo & Carney, 2005) . One of the main functions of this enzyme is the removal of long-chain aliphatic aldehydes through oxidation into fatty acids (Rizzo, 2001) . FALDH deficiency causes a severe disturbance of fatty aldehyde metabolism leading to a variety of clinical features. The primary symptoms are ichthyosis, spasticity, and intellectual disability (Sjogren & Larsson, 1957) . Furthermore, ocular problems (retinopathy, photophobia, reduced visual acuity) and
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. other neurological abnormalities are frequently reported (Fuijkschot et al., 2012; Van der Veen et al., 2010; Willemsen et al., 2000) . Clinical manifestations are usually static although neurological symptoms can progress over time (Fuijkschot et al., 2012) .
FALDH is a membrane-bound homodimeric NAD+-dependent enzyme (E.C.1.2.1.48). Two splice variants determine its subcellular location. A major transcript encodes a 485 amino acid protein integrated into the endoplasmic reticulum, whereas the minor (<10%) transcript encodes a 508 amino acid variant with an elongated carboxy-terminus that guides the enzyme to the peroxisomal membrane (Rogers, Markova, De Laurenzi, Rizzo, & Compton, 1997) .
Homodimer formation of FALDH is a requirement for the enzyme to be enzymatically active, and for correct alignment along membrane Human Mutation. 2019;40:177-186.
wileyonlinelibrary.com/journal/humu lipid bilayers (Keller et al., 2010 (Keller et al., , 2014 . Correct orientation and membrane interaction of FALDH is mediated by a large dimerization interface and is supported by a carboxy-terminal hydrophobic alpha helix which likely constrains conformational space for substrates and facilitates traffic of long-chain fatty aldehydes toward the catalytic site (Keller et al., 2014) . Each subunit of FALDH has a cofactor binding site which is oriented toward the cytosol, and a substrate binding funnel reaching toward the membranes.
Impaired FALDH function leads to disruption of the cell's ability to detoxify fatty aldehydes (Rizzo, 2014) , which have a high capacity of undesired nonenzymatic reactivity (Keller, Piedrafita, & Ralser, 2015) . Fatty aldehydes originate from diverse metabolic processes (Keller et al., 2014) such as the catabolism of ether lipids and plasmalogens (Keller, Watschinger, Golderer, Werner-Felmayer, & Werner, 2013; Rizzo, Heinz, Simon, & Craft, 2000) . Accumulation of fatty aldehydes leads to the formation of Schiff base adducts with free amino groups of macromolecules such as proteins and lipids, disrupting their biochemical functions (James & Zoeller, 1997) . It has also been shown that fatty aldehydes in SLS patient cells are converted into fatty alcohols rather than fatty acids, which represents an additional source for cytotoxic effects (Keller et al., 2012; Rizzo et al., 2008) .
Therapeutic options for SLS are currently limited to symptomatic treatment of cutaneous and neurologic manifestations (Rizzo, 2016) .
Oral retinoids and various topical treatments (e.g., urea containing creams) are used for skin manifestations (Gånemo, Jagell, & Vahlquist, 2009 ). Spasticity is treated with surgical procedures, botulinum toxin injections, and oral or intrathecal baclofen .
Seizures are controlled with antiepileptics .
Novel innovative and prospective therapeutic approaches for SLS are currently under consideration and will potentially help to ease the burden of the severe symptoms of affected patients (Rizzo, 2016 which serves as an international standard for denotation of DNA, RNA, and protein variants. For phenotypic data, the Human Phenotype Ontology (HPO) was used as a standardized vocabulary (Köhler et al., 2014) . HPO terms are hierarchically structured in a tree-like manner. Due to a strong variability of the terms used to describe individual SLS phenotypes, some generalizations and simplifications were introduced, as described in Table 1 .
Database structure
Finally, all information was collected in the web-based Leiden Open and about individual patients, including for example the respective genotype, zygosity, germline/somatic/de novo, and segregation.
RESULTS AND DISCUSSION

Individuals
In total, 178 individuals with 90 unique pathogenic SLS variants in ALDH3A2 were recorded. One hundred and thirty three of these patients (74.7%) carried homozygous SLS variants while 45 (25.3%) were compound heterozygous. In one individual with typical clinical SLS features, only one heterozygous SLS variant was identified;
this individual is expected to carry an as yet unidentified second pathogenic variant . Information on the biological sex was available for 147 SLS patients published, with a balanced male (n = 74, 50.3%) to female (n = 73, 49.7%) ratio (Chi-square: 0.001; p-value = 0.974). Information on the geographic country of origin was available for 141 patients; patients came from 25 different countries with hotspots in Sweden and the Netherlands indicating increased incidence rates and/or centers active in SLS research (see Figure 1 , Supp. Table S1 ). For the remaining cases, only the location of the respective publishing institution is known and was not included into this analysis.
Beside the country of origin, also the ethnic origin of patients would be of interest, which is however only rarely reported.
Pathogenic variants in the ALDH3A2 gene
The ALDH3A2 Figure 2A ). Thus, all pathogenic ALDH3A2 variants described so far affect both splice transcripts of FALDH, with no pathogenic variant reported for the (extended) peroxisomal transcript variant 1 (NM_001031806.1). Compared to other autosomal recessive metabolic conditions, the proportion of SLS frame shift variants predicted to completely remove enzyme function is relatively high (n = 29; 32.2%). Missense variants (n = 30, 33.3%) also account for approximately one-third of pathogenic variants, followed by intronic (n = 14, 15.6%), nonsense (n = 9; 10.0%), in-frame insertions/deletions (n = 5; 5.6%), and large rearrangements (n = 3; 3.3%) (see Figure 2B ).
The FALDH structure consists of three large domains (catalytic, cofactor binding, and dimerization), and additional functional units such as the gatekeeper helix and the membrane anchor. As illustrated in Figure 2C, and Pro-315 are more than 10Å apart from each other, and the flexibility of the lysine side chain length could reduce this distance to 5Å.
However, there is no indication of a compound heterozygous-specific interaction between these two variants, as the clinical phenotype does not differ from other genotypes involving these variants.
Phenotypic spectrum of the Sjögren-Larsson syndrome
Phenotypic information in addition to the genetic information was After merging of redundant features, in total, 65 different symptoms were described in at least one patient, 9 of which can be considered as main symptoms because they mostly are independent from each other and were reported in at least 15% of cases (see Figure 3). The three symptoms generalized ichthyosis, spasticity, and intellectual disability (sometimes termed slightly differently) are regarded as the characteristic symptoms for SLS in the literature and were also present in nearly every patient of the present study. Other symptoms or signs such as "Yellow/white lesions of the retina," "Pruritus," "Photophobia," "Abnormal CNS myelination," "Preterm birth," and "Seizures"
were reported with declining frequency. Some disease features were more likely to be explicitly excluded (see Figure 3 , Supp. Table S2 ).
Especially for "Yellow/white lesions of the retina" and "Seizures," a noticeable number of cases were reported in which these symptoms were reported as absent (n = 22 and 44, respectively). Conversely, "Pruritus," "Premature birth," "Abnormal CNS myelination," "Photophobia," and "Seizures" were neither reported nor excluded in more than 50% of cases (Supp . Table S2 ).
For the three main symptoms of SLS, many of the publications state degrees of severity or more detailed information. A comprehensive comparison of these gradations proved to be difficult as the specifications used in different papers are heterogeneous, indicating the need of standardized guidelines for future reporting of clinical features (see Table S2 below). However, converting the classification information into three broad categories "mild," "moderate," and "severe" allowed for a rough assessment of their actual diversity.
For 97 patients, more detailed clinical information regarding "generalized ichthyosis" was available, which was described as mild in 17 patients (17.5%), moderate in 21 patients (21.6%), and severe in 59 patients (60.8%). Ichthyosis often goes hand in hand with "Pruritus," defining the abnormalities of the integument in SLS. However, pruritus was only reported in about 40% of patients, and its occurrence was not correlated with the severity of the Ichthyosis phenotype. In 17 cases also, "hypohidrosis" (HP:0000966) was mentioned as a rare symptom connected to ichthyosis. The severity of "spasticity" was specified in detail in 107 cases and described as mild in 3 cases (2.8%) moderate in 32 cases (29.9%), and severe in 72 (67.3%) cases. "Intellectual disability" was denoted in detail in 84 patients, divided into mild in 26 (31.0%), moderate in 30 (35.7%), and severe in 28 (33.3%) patients.
Only four publications Nakajima et al., 2011; Papathemeli et al., 2017; Willemsen et al., 2001) provide detailed information about the cognitive status including IQ measurements of some of the reported patients. The median IQ of a total of 12 patients included in three of these studies was 54.5 (range: 39-65). Three patients without intellectual disability (IQ: 95, 83, 84) according to the former DSM-IV definition were excluded from this calculation Willemsen et al., 2001) . According to other publications (Alió et al., 2006; Aoki et al., 2000) Willemsen, 2018; van Domburg et al., 1999) , the phenotype "premature birth" was only reported for 35 patients. Duration of gestation was stated for 32 of these patients, with an average duration of 34 weeks.
Normal length of pregnancy was stated in 15 cases. In light of the results of an earlier analysis (Staps et al., 2018) , it is likely that premature birth represents a SLS phenotype that is strongly under-reported.
For 64 patients, "abnormal CNS myelination" was reported. The precise location of the deficit was indicated for 34 patients (n = 34). In 30 of these cases (88.2%), the periventricular region of the brain was affected. Together with abnormalities in magnetic resonance imaging (MRI), this phenotype might be under-reported because of lack of technical or financial possibilities (see below). Furthermore, dysmyelination develops with time and may not yet be present in infants; conversely, myelination may mature with age leading to normal MRI findings after an earlier pathological scan (van Domburg et al., 1999) .
In earlier studies, it has been reported that about 40% of SLS patients are affected by one or more "seizures" (Rizzo, 2001) . This is in good agreement with the stated percentage of affected and unaffected individuals (37.1% had seizures) in the database. Seizures in SLS patients are typically grand mal and represent a manifestation that is not easily missed, indicating that the frequency of 35-40% is close to the true incidence at least for classical SLS patients.
Apart from the main clinical features shown in Figure 3 (values in Supp. Table S2 ) and discussed above, there are also symptoms that were reported less frequently (a full list can be found in Supp. Table S3 ). Sometimes these symptoms may occur due to other comorbidities but others are likely also associated with SLS. Several main features of SLS fall within the HPO category of "abnormalities of the nervous system," of which "intellectual disability" is for example sometimes accompanied by the less frequently reported "poor speech" or "dysarthria" (HP:0002465, HP:0001260, n = 34) phenotype. Additionally to the main symptoms "seizures" and "spasticity" there is a range of roughly associated features reported, including different abnormalities of muscle tone (HP:0001276, HP:0001252, HP:0008936, HP:0000297, n = 17), "hyperreflexia" (HP:0006801, HP:0001347, n = 38), "contractures of the joints of the lower limbs" (HP:0005750, n = 9), "ankle clonus"/"myoclonus" (HP:0011448, HP:0001336, n = 3), and "dysphagia" (HP:0002015, n = 1). The nature of these symptoms generates a large intrinsic overlap with the HPO category of "abnormalities of the musculature." Abnormalities of the eye in SLS patients are mainly reported as "yellow/white lesions of the retina"
and "photophobia" but include terms such as "reduced visual acuity" (HP:0007663, n = 14), "abnormal colour vision" (HP:0000551, n = 4), "hypopigmentation of the fundus" (HP:0007894, n = 1), or "corneal opacity" (HP:0007957, n = 1). In few patients, "hypertelorism"
(HP:0000316, n = 2), and "strabismus" (HP:0000486, n = 2), "proptosis" (HP:0000520, n = 1), and "ptosis" (HP:0000508, n = 1) were stated.
Abnormalities of the skeletal system, head, and limbs have been reported in a considerable number of cases. Partly these could be related to chronically increased muscle tone due to spasticity, but also other pathomechanisms (e.g., defects in developmental signaling pathways) are possible. A variety of different rare features that fall within this category have been reported, including "foot deformities" (HP:0001760, HP:0001763, n = 26), abnormalities of the spine (HP:0002751, HP:0002808, HP:0002650, n = 10), chest deformities (HP:0000767, HP:0000768, n = 3), abnormalities of the skull (HP:0000256, HP:0000252, HP:0000268, n = 3), and "facial dysmorphism" (HP:0001999, n = 2). In contrast, other symptoms have merely been described in single cases including "dislocated radial head"
(HP:0003083), "short 5th finger" (HP:0009237), "short metatarsal bones" (HP:0010743), and "congenital hip dislocation" (HP:0001374).
In summary, the spectrum of rare clinical features described in SLS patients in the literature is broad but their reporting is sometimes spurious and depends on the clinical interests, testing capabilities, and the precise use of established terminology. Thus, although some characteristics may appear to co-occur with specific genetic variants they may be more likely the result of a testing and reporting bias, rather than an actual genotype-phenotype relationship.
Does residual FALDH activity correlate with the phenotypic spectrum?
Several publications provided information about the residual enzymatic activity associated with the respective SLS variant (Carney, Wei, & Rizzo, 2004; Davis et al., 2013; De Laurenzi et al., 1996; Didona et al., 2007; Kariminejad et al., 2017; Köhler et al., 2017; Rizzo et al., 2010; Sarret et al., 2012; Tsukamoto et al., 1997; Willemsen et al., 2001) . In essence, two approaches were used to determine enzymatic activity of FALDH: either quantification in cultured cells from patients (predominantly fibroblasts), or over-expression of mutant FALDH in mammalian, insect, or bacterial cells.
Data on residual enzymatic activity was available for 46 out of the 85 variants (54%), with activity values ranging from 0% up to 23% compared to wild-type. Using activity data for subgrouping patients, no significant phenotype differences were apparent in patients with genotypes predicting different levels of enzyme function. In general, there appears to be only limited quantitative comparability between the residual activity results obtained in different studies. One reason for this could lie within the relatively broad range of enzyme activities measured in cells, potentially resulting from different methodologies as well as natural variability. Furthermore, in cell homogenates there can be as much as 8% of residual long-chain aldehyde oxidizing activity due to other non-FALDH aldehyde dehydrogenases . Thus, residual FALDH activity might be more precisely determined by measuring over-expressed FALDH. Therefore, it cannot be excluded that the lack of genotype-phenotype correlation is at least partly caused by the variable quantitative scales used for describing phenotypes and enzyme activities. Systematic and comprehensive reporting of SLS cases in the future is required to obtain more reliable data.
Suggestions for a comprehensive documentation of SLS patient data
In the course of this study, one of the strongest limitations was the For phenotype data, we recommend using the HPO nomenclature (Köhler et al., 2017) . At a minimum, the 9 most common symptoms (see Figure 3 ) should be checked, and their occurrence should be confirmed or explicitly excluded along with the respective ages of onset.
The respective severity of ichthyosis, intellectual disability, and spasticity should be stated together with the criteria used for this assessment. Different scales are available for ichthyosis (Ezzedine et al., 2012; Kamalpour, Rice, Pavlis, Veledar, & Chen, 2010; Marukian et al., 2017; Paller et al., 2017) and spasticity (Ashworth, 1964; Bohannon & Smith, 1987; Boyd & Kerr Graham, 1999) . For classifying intellectual disability, the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (Regier, Kuhl, & Kupfer, 2013) can serve as a well-established guideline.
CONCLUSION
We have established a patient-centered database for pathogenic variants in the ALDH3A2 gene, which contains both, genotype information for individual patients as well as clinical data. By including all published SLS cases that fulfil the required selection and quality criteria, this study paves the way for the SLS research community to further feed into a homogeneous open-access database. The collected information highlights the insular occurrence of certain (mostly homozygous) genotypes in Sweden, Western Europe, Brazil, and Israel caused by independent founder SLS variants, but also, for example, the mixing of the Swedish with the Western European variants in cases centered around the Netherlands. The low minor allele frequency of "common" SLS variants emphasized the rarity of this disorder. By only including genetically well described cases into this database, we were able to ensure highest data quality, with the limitation that cases with incomplete data in regard to the here applied inclusion criteria could not be considered.
We find that the three major symptoms, i.e. ichthyosis, intellectual disability, and spasticity are readily documented. However, their detailed classifications, as well as the occurrence of other phenotypic features, are highly variable due to biological heterogeneity and inconsistency in reporting. The resulting broad phenotypic spectrum does not allow identifying genotype-phenotype correlations, which may be at least partially due to incomplete clinical data and difficulties in measuring residual enzyme function. Based on the here assembled data, we established a "SLS case report checklist" (Supp. Document S1) aimed to assist with generating comprehensive patient descriptions in the future. Moreover, with increasing application of whole exome and whole genome sequencing, it is possible that patients with ALDH3A2related variant forms of SLS lacking the typical clinical features will be identified in the future.
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